Ruth A. Roberts, Mamta Behl, Helena T. Hogberg, et al. Use of new approach methodologies (NAMs) in epilepsy research and seizure risk assessment. Drug Discovery Today. 2025;31(1):104569. doi:10.1016/j.drudis.2025.104569
Kang Zhang, Xin Yang, Yifei Wang, et al. Artificial intelligence in drug development. Nature Medicine. 2025;31(1):45-59. doi:10.1038/s41591-024-03434-4
Catharine E. Krebs, Kathrin Herrmann. Confronting the bias towards animal experimentation (animal methods bias). Frontiers in Drug Discovery. 2024;4. doi:10.3389/fddsv.2024.1347798
Eric Vallabh Minikel, Jeffery L. Painter, Coco Chengliang Dong, Matthew R. Nelson. Refining the impact of genetic evidence on clinical success. Nature. 2024:1-6. doi:10.1038/s41586-024-07316-0
Ingrid Berg, Pia Härvelid, Wolfgang Emanuel Zürrer, Marianna Rosso, Daniel S. Reich, Benjamin Victor Ineichen. Which experimental factors govern successful animal-to-human translation in multiple sclerosis drug development? A systematic review and meta-analysis. eBioMedicine. 2024;110. doi:10.1016/j.ebiom.2024.105434
Pelin L. Candarlioglu, Louise Delsing, Lauren Gauthier, et al. Application of microphysiological systems for nonclinical evaluation of cell therapies. Alternatives to Animal Experimentation. 2024;41(3):469-484. doi:10.14573/altex.2402201
Carla CunÃ-López, Romal Stewart, Anthony R. White, Hazel Quek. 3D in vitro modelling of human patient microglia: A focus on clinical translation and drug development in neurodegenerative diseases. Journal of Neuroimmunology. 2023;375:578017. doi:10.1016/j.jneuroim.2023.578017
Marit Keuper-Navis, Markus Walles, Birk Poller, et al. The application of organ-on-chip models for the prediction of human pharmacokinetic profiles during drug development. Pharmacological Research. 2023;195:106853. doi:10.1016/j.phrs.2023.106853
Kimberly A. Homan. Industry Adoption of Organoids and Organs-on-Chip Technology: Toward a Paradox of Choice. Advanced Biology. 2023;7(6):2200334. doi:10.1002/adbi.202200334